Literature DB >> 1649319

Monoclonal antibodies to gp100 inhibit penetration of human herpesvirus 6 and polykaryocyte formation in susceptible cells.

L Foà-Tomasi1, A Boscaro, S di Gaeta, G Campadelli-Fiume.   

Abstract

We report the derivation and properties of a monoclonal antibody (MAb 2E4) which neutralizes human herpesvirus 6 (HHV-6). MAb 2E4 precipitated from lysates of infected cells a glycosylated polypeptide 100,000 in apparent molecular weight and minor components of 80,000, and 32,500. The predominant reactive protein after a pulse was the 100,000-molecular-weight peptide designated as gp100. The smaller polypeptides appeared in the precipitate predominantly after a chase. MAb 2E4 neutralized HHV-6 infectivity in the presence and in the absence of complement, and it inhibited the penetration of virus into the cells. Addition of MAb 2E4 as late as 6 h postinfection inhibited the formation of large polykaryocytes typical of HHV-6-infected cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649319      PMCID: PMC248845     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  PENETRATION OF HERPES SIMPLEX VIRUS INTO HUMAN EPIDERMOID CELLS.

Authors:  A S HUANG; R R WAGNER
Journal:  Proc Soc Exp Biol Med       Date:  1964 Aug-Sep

2.  Entry of herpes simplex virus 1 in BJ cells that constitutively express viral glycoprotein D is by endocytosis and results in degradation of the virus.

Authors:  G Campadelli-Fiume; M Arsenakis; F Farabegoli; B Roizman
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

3.  Generation of an inverting herpes simplex virus 1 mutant lacking the L-S junction a sequences, an origin of DNA synthesis, and several genes including those specifying glycoprotein E and the alpha 47 gene.

Authors:  R Longnecker; B Roizman
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

4.  Excretion of non-infectious virus particles lacking glycoprotein H by a temperature-sensitive mutant of herpes simplex virus type 1: evidence that gH is essential for virion infectivity.

Authors:  P J Desai; P A Schaffer; A C Minson
Journal:  J Gen Virol       Date:  1988-06       Impact factor: 3.891

5.  Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion.

Authors:  W H Cai; B Gu; S Person
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

6.  Isolation of human lymphotropic herpesviruses from Uganda.

Authors:  R G Downing; N Sewankambo; D Serwadda; R Honess; D Crawford; R Jarrett; B E Griffin
Journal:  Lancet       Date:  1987-08-15       Impact factor: 79.321

7.  Clustering of genes dispensable for growth in culture in the S component of the HSV-1 genome.

Authors:  R Longnecker; B Roizman
Journal:  Science       Date:  1987-05-01       Impact factor: 47.728

8.  The properties and sequence of glycoprotein H of herpes simplex virus type 1.

Authors:  U Gompels; A Minson
Journal:  Virology       Date:  1986-09       Impact factor: 3.616

9.  Antibody reactivity with HBLV (HHV-6) in U.S. populations.

Authors:  C Saxinger; H Polesky; N Eby; S Grufferman; R Murphy; G Tegtmeir; V Parekh; S Memon; C Hung
Journal:  J Virol Methods       Date:  1988-09       Impact factor: 2.014

10.  A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells.

Authors:  M W Ligas; D C Johnson
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

View more
  11 in total

1.  The 85-kilodalton phosphoprotein (pp85) of human herpesvirus 7 is encoded by open reading frame U14 and localizes to a tegument substructure in virion particles.

Authors:  A Stefan; P Secchiero; T Baechi; W Kempf; G Campadelli-Fiume
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Human herpesvirus 6 variant A glycoprotein H-glycoprotein L-glycoprotein Q complex associates with human CD46.

Authors:  Yasuko Mori; Xuwei Yang; Pilailuk Akkapaiboon; Toshiomi Okuno; Koichi Yamanishi
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  Determination and analysis of the complete nucleotide sequence of human herpesvirus.

Authors:  J Nicholas
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 4.  Immune response to HHV-6 and implications for immunotherapy.

Authors:  Aniuska Becerra; Laura Gibson; Lawrence J Stern; J Mauricio Calvo-Calle
Journal:  Curr Opin Virol       Date:  2014-10-27       Impact factor: 7.090

5.  Intracellular processing of human herpesvirus 6 glycoproteins Q1 and Q2 into tetrameric complexes expressed on the viral envelope.

Authors:  Pilailuk Akkapaiboon; Yasuko Mori; Tomohiko Sadaoka; Sayoko Yonemoto; Koichi Yamanishi
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 6.  Human herpesvirus 6: An emerging pathogen.

Authors:  G Campadelli-Fiume; P Mirandola; L Menotti
Journal:  Emerg Infect Dis       Date:  1999 May-Jun       Impact factor: 6.883

7.  Biological roles of the major capsid proteins and relationships between the two existing serotypes of infectious bursal disease virus.

Authors:  S K Reddy; A Silim; M J Ratcliffe
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Trafficking to the plasma membrane of the seven-transmembrane protein encoded by human herpesvirus 6 U51 gene involves a cell-specific function present in T lymphocytes.

Authors:  L Menotti; P Mirandola; M Locati; G Campadelli-Fiume
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  The human herpesvirus 6 U100 gene product is the third component of the gH-gL glycoprotein complex on the viral envelope.

Authors:  Yasuko Mori; Pilailuk Akkapaiboon; Xuwei Yang; Koichi Yamanishi
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Human herpesvirus 6 variant A but not variant B induces fusion from without in a variety of human cells through a human herpesvirus 6 entry receptor, CD46.

Authors:  Yasuko Mori; Tsukasa Seya; Hong Lan Huang; Pilailuk Akkapaiboon; Panadda Dhepakson; Koichi Yamanishi
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.